FIRST TWO HEMOPHILIA B PATIENTS RECEIVE CSL BEHRING’S GENE THERAPY HEMGENIX IN FRANCE
Global biotechnology leader CSL Behring announced that two hemophilia B patients were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France.
According to a statement, this milestone achievement m…